US EditionGLP-1 Receptor Agonists Likely Have Little or No Effect on Obesity-Related Cancer Risk, Research Shows
A review of 48 trials with over 51,000 GLP-1 drug users found little or no effect on risk for 13 obesity-related cancers, with follow-up averaging 70 weeks.
- On December 8, a pooled analysis found GLP-1 receptor agonists probably have little or no effect on risk of the 13 obesity-related cancers, published in the Annals of Internal Medicine.
- Earlier observational research suggested GLP-1 drugs such as Ozempic and Zepbound might lower cancer risk, prompting investigators to test if GLP-1–driven weight loss reduces obesity-related cancer risk despite possible confounding.
- The analysis pooled data from 48 randomized controlled trials involving 94,245 participants, with more than 51,000 on GLP-1 medications and nearly 43,000 on placebo, and a median follow-up of 70 weeks; most trials were short and not designed to assess cancer outcomes.
- Cancer experts responded that Dr. Bassel El‑Rayes said the results reassure current GLP-1 drug users, while the U.S. Food and Drug Administration cautions those with thyroid cancer history to avoid certain drugs and recommends longer monitoring.
- Given the study's limitations, researchers urge longer-term cancer-specific studies since nearly 50 trials were not designed to measure outcomes and a thyroid cancer signal appeared in one study.
19 Articles
19 Articles
GLP-1 receptor agonists likely have little or no effect on obesity-related cancer risk, research shows
A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity.
NBC Connecticut
NBC BostonGLP-1 drugs have ‘little or no effect' on risk of obesity-related cancers, study suggests
Despite previous excitement around a potential link between GLP-1 drugs and a reduced risk of cancer, new research suggests the popular medications “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers. The findings, published Monday in the Annals of Internal Medicine, may seem counterintuitive, said co-author Dr. Cho-Han Chiang, who conducted the study earlier this year as an internal medicin…
NBC Chicago
GLP-1 drugs have ‘little or no effect’ on risk of obesity-related cancers, study suggests
Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related cancers, new research...
Study indicates that drugs such as Ozempic would have little effect on reducing the risk of obesity-related cancers, despite their weight benefits
GLP-1s and Cancer: Meta-analysis Shows Little or No Link
The systematic review and meta-analysis of 48 trials involving 94,245 individuals show little or no effect of GLP-1 RA treatment on the risk for obesity-related cancers. Medscape Medical News Source link : https://www.medscape.com/viewarticle/glp-1s-and-cancer-meta-analysis-shows-little-or-no-link-2025a1000yie?src=rss Author : Publish date : 2025-12-09 13:37:00 Copyright for syndicated content belongs to the linked Source. The post GLP-1s and Ca…
Coverage Details
Bias Distribution
- 85% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
